Key Insights

Highlights

Success Rate

96% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

3.6%

1 terminated out of 28 trials

Success Rate

96.0%

+9.5% vs benchmark

Late-Stage Pipeline

32%

9 trials in Phase 3/4

Results Transparency

0%

0 of 24 completed with results

Key Signals

96% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (11)
P 1 (2)
P 2 (3)
P 3 (7)
P 4 (2)

Trial Status

Completed24
Unknown3
Terminated1

Trial Success Rate

96.0%

Benchmark: 86.5%

Based on 24 completed trials

Clinical Trials (28)

Showing 20 of 20 trials
NCT06120816Phase 1CompletedPrimary

Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis

NCT03250923Phase 1UnknownPrimary

CelAgace™ OraRinse Solution for Treatment of Candidiasis

NCT00235053Phase 4Completed

Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID

NCT00001065Phase 2CompletedPrimary

A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole

NCT00000951Phase 4CompletedPrimary

A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush

NCT04410250Not ApplicableUnknown

Effect of Oral Hygienization in Newborn on Candida Spp Colonization

NCT03894839Not ApplicableCompletedPrimary

Evaluation of the Effect of Different Cleaning and Disinfection Procedures on the Involvement of Candida Species

NCT03873753Not ApplicableUnknownPrimary

Relationship Between Oral Hygiene in Newborns and Candida Spp.

NCT02818803Phase 3CompletedPrimary

Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic

NCT00666185Phase 3CompletedPrimary

Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis

NCT00665639Phase 3CompletedPrimary

Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis

NCT02184351Phase 3CompletedPrimary

Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis

NCT00612963CompletedPrimary

Novel Rinse to Treat in Oral Candidiasis in Cancer Patients

NCT00001448CompletedPrimary

The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection

NCT00001812Phase 3CompletedPrimary

A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2

NCT00128323Phase 3CompletedPrimary

A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis

NCT00002057Not ApplicableCompletedPrimary

Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC

NCT00002293Not ApplicableCompletedPrimary

A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

NCT00004781Completed

Oral Manifestations of Human Immunodeficiency Virus Infection in High Risk Groups

NCT00005920Phase 2TerminatedPrimary

Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole

Scroll to load more

Research Network

Activity Timeline